title: Camouflage and sabotage: tumor escape from the immune system.
abstract: The field of tumor immunology has made great progress in understanding tumor immune interactions. As a consequence a number of immuno-therapeutic approaches have been successfully introduced into the clinic and a large number of promising therapeutic strategies are investigated in ongoing clinical trials. Evaluation of anti-tumor immunity in such trials as well as in animal models has shown that tumor escape from immune recognition and tumor-mediated suppression of anti-tumor immunity can pose a significant obstacle to successful cancer therapy. Here, we review mechanisms of tumor immune escape and immune-subversion with a focus on the research interests in our laboratory: loss of MHC class I on tumor cells, increased oxidative stress, recruitment of myeloid-derived suppressor cells, and regulatory T cells.
authors.affiliation: Department of Oncology and Pathology, Cancer Center Karolinska R8:01, Karolinska Institutet, Karolinska University Hospital, 17176 Stockholm, Sweden. Isabel.Poschke@ki.se
authors.forename: Isabel
authors.initials: I
authors.lastname: Poschke
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Mougiakakos
authors.forename: Rolf
authors.initials: R
authors.lastname: Kiessling
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D015395:Histocompatibility Antigens Class I / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007107:Immune System; D007165:Immunosuppression Therapy; D007167:Immunotherapy / Q000639:trends; D022423:Myeloid Cells / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D018384:Oxidative Stress; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D019139:Tumor Escape
chemical_list: D015395:Histocompatibility Antigens Class I